[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account
arrow_back

Go back to trials list

A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants With Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma


Description

The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.

Trial Eligibility

Inclusion Criteria: * Participants with pathologically confirmed high-risk R/R cHL, after non-response to or failure of 1or more lines of standard therapy. * Participants with pathologically confirmed R/R NHL after non-response to or failure of 1or more lines of standard therapy, including, but not limited to, R/R primary mediastinal B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), mediastinal gray zone lymphoma (MGZL), anaplastic large cell lymphoma (ALCL), or peripheral T-cell lymphoma (PTCL). * Participants with pathologically confirmed R/R NHL after non-response to or failure of 2 or more lines of standard therapy, including Burkitt lymphoma (blast count \<25% malignant Burkitt cells and/or per the investigator's clinical assessment of risk status), lymphoblastic lymphoma (blast count \< 25% of marrow nucleated cells and/or per the investigator's clinical assessment of risk status), NK/T-cell lymphoma (nasal and non-nasal NK/T-cell lymphoma subtypes, but not aggressive NK/T-cell leukemia/lymphoma subtype). * The participant's current disease state must be R/R to standard therapy. * Participants must have measurable PET positive disease in both cHL and NHL cohorts. Exclusion Criteria: * Primary CNS lymphoma of the brain or spinal cord, and secondary CNS lymphoma (ie, from systemic non-Hodgkin lymphoma) involving the brain, spinal cord, or with leptomeningeal seeding. * Prior treatment with an anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways, with the exception of anti-PD(L)-1 targeted therapies. * Prior treatment with lymphocyte activation gene-3 (LAG-3)-targeted agents. * Participants with clinically significant systemic illnesses unrelated to the cancer as judged by the investigators, which would compromise the participant's ability to tolerate the study treatment. * Participants with autoimmune disease. * Prior allogeneic bone marrow transplantation. Other protocol-defined inclusion/exclusion criteria apply

Study Info

Organization

Bristol-Myers Squibb


Primary Outcome

Incidence of dose-limiting toxicities (DLTs)


Outcome Timeframe Up to 135 days following last dose

NCTID NCT05255601

Phases PHASE1,PHASE2

Primary Purpose TREATMENT

Start Date 2022-09-13

Completion Date 2028-07-05

Enrollment Target 68

Interventions

DRUG Relatlimab

DRUG Nivolumab

Locations Recruiting

Phoenix Childrens Hospital PCH - Phoenix Childrens Medical Group - Hematology Oncology

United States, Arizona, Phoenix


Lucile Packard Childrens Hospital - Stanford University

United States, California, Palo Alto


Yale University

United States, Connecticut, New Haven


Local Institution - 0061

United States, Delaware, Wilmington


Golisano Children's Hospital of Southwest Florida

United States, Florida, Fort Myers


Interested in joining this trial?

Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.

newsletter icon

Get the latest thought leadership on your Leukemia delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.